Itai Benhar

Prof. Itai Benhar

School of Molecular Cell Biology and Biotechnology, the Georg S. Wise Faculty of Life Sciences
+1

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2011 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
LBL. Bachmetov
L. Bachmetov
MGM. Gal‐Tanamy
M. Gal‐Tanamy
ASA. Shapira
A. Shapira
MVM. Vorobeychik
M. Vorobeychik
TGT. Giterman‐Galam
T. Giterman‐Galam
RZRomy Zemel
Romy Zemel

25 April 2012 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
LBLior Brimberg
Lior Brimberg
Itai BenharItai Benhar
Itai Benhar
AMAdita Mascaro-Blanco
Adita Mascaro-Blanco
KAKathy Alvarez
Kathy Alvarez
DLDafna Lotan
Dafna Lotan
DJDaphna Joel
Daphna Joel
Group A streptococcal (GAS) infections and autoimmunity are associated with the onset of a spectrum of neuropsychiatric disorders in children, with the prototypical disorder being Sydenham chorea (SC). Our aim was to develop an animal model that resembled the behavioral, pharmacological, and immunological abnormalities of SC and other streptococcal-related neuropsychiatric disorders. Male Lewis rats exposed to GAS antigen exhibited motor symptoms (impaired food manipulation and beam walking) and compulsive behavior (increased induced-grooming). These symptoms were alleviated by the D2 blocker haloperidol and the selective serotonin reuptake inhibitor paroxetine, respectively, drugs that are used to treat motor symptoms and compulsions in streptococcal-related neuropsychiatric disorders. Streptococcal exposure resulted in antibody deposition in the striatum, thalamus, and frontal cortex, and concomitant alterations in dopamine and glutamate levels in cortex and basal ganglia, consistent with the known pathophysiology of SC and related neuropsychiatric disorders. Autoantibodies (IgG) of GAS rats reacted with tubulin and caused elevated calcium/calmodulin-dependent protein kinase II signaling in SK-N-SH neuronal cells, as previously found with sera from SC and related neuropsychiatric disorders. Our new animal model translates directly to human disease and led us to discover autoantibodies targeted against dopamine D1 and D2 receptors in the rat model as well as in SC and other streptococcal-related neuropsychiatric disorders.

1 February 2001 in Biotechnology Advances
Verified
Journal Article
Closed access
Itai BenharItai Benhar
Itai Benhar

1 October 2002 in Journal of Molecular Biology
Verified
Journal Article
Closed access
YMYariv Mazor
Yariv Mazor
SGSharon Gilead
Sharon Gilead
Itai BenharItai Benhar
Itai Benhar
EGEhud Gazit
Ehud Gazit

20 April 2015 in Gut
Verified
Journal Article
Closed access
PDF file
SBShomron Ben-Horin
Shomron Ben-Horin
MYMiri Yavzori
Miri Yavzori
Itai BenharItai Benhar
Itai Benhar
EFElla Fudim
Ella Fudim
OPOrit Picard
Orit Picard
YCYehuda Chowers
Yehuda Chowers
Objective The cross-immunogenicity of the recently approved infliximab-biosimilar Remsima (CT-P13) with the originator drug Remicade is still unknown. Design Sera of patients with IBD with or without measurable anti-Remicade antibodies to infliximab (ATI) were tested for their cross-reactivity to two batches of Remsima. Experiments were repeated after deglycosylation of Remicade/Remsima, IgG purification, excipients’ dialysis and monomer purification by size exclusion chromatography. Anti-Remicade antibodies were tested for their functional inhibition of TNF-α binding by Remsima/Remicade by competition assay. Cross-reactivity of anti-adalimumab antibodies with Remicade/Remsima was also investigated. Results 125 patients’ and controls’ sera were tested (median age 31 years, IQR 24.5–39.5). All 56 anti-Remicade ATI-negative controls (14 healthy individuals, 42 patients with IBD) were also negative for anti-Remsima ATI. All 69 positive anti-Remicade IBD sera were cross-reactive with Remsima. ATI titres against Remicade or Remsima were strongly correlated (r values between 0.92 and 0.99, p<0.001 for all experiments, Spearman's correlation test). The background ELISA signal for Remsima was slightly higher compared with Remicade in negative controls (1.25±0.6 µg/mL vs 0.76±0.5 µg/mL, respectively, p<0.001), and persisted after deglycosylation, dialysis or protein size filtration, but abolished by IgG purification and significantly diminished by monomer purification. Anti-Remicade ATIs of patients with IBD (n=10) exerted similar functional inhibition on Remsima or Remicade TNF-α binding capacity (p=NS for all inhibition curve points). Antibodies-to-adalimumab in adalimumab-treated patients with IBD (n=7) did not cross-react with either Remicade or Remsima. Conclusions Anti-Remicade antibodies in patients with IBD recognise and functionally inhibit Remsima to a similar degree, suggesting similar immunogenicity and shared immunodominant epitopes on these two infliximab agents. In contrast, anti-adalimumab antibodies do not cross-react with Remsima or Remicade.

1 September 2001 in Journal of Molecular Biology
Verified
Journal Article
Closed access
HBHoracio Bach
Horacio Bach
YMYariv Mazor
Yariv Mazor
SSShelly Shaky
Shelly Shaky
ASAtar Shoham-Lev
Atar Shoham-Lev
YBYevgeny Berdichevsky
Yevgeny Berdichevsky
Itai BenharItai Benhar
Itai Benhar